Report ID: 10352320 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
Global monoclonal antibodies market will reach $329.6 billion by 2030, growing by 10.9% annually over 2020-2030, driven by the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
Highlighted with 83 tables and 84 figures, this 165-page report “Global Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Region.
Based on Source, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Human
• Humanized
• Chimeric
• Murine
Based on Category, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Branded mAbs
• Biosimilar mAbs
Based on Production Type, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• In Vitro Production
• In Vivo Production
Based on Application, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Ovarian Cancer
o Other Cancer Types
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Other Applications
By End User, the global market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Hospitals
• Research Institutes
• Other End Users
Geographically, the following regions together with the listed national/local markets are fully investigated:
• North America (U.S., Canada, and Mexico)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa, Other Nations)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Source, Application, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 9
1.1 Industry Definition and Research Scope 9
1.1.1 Industry Definition 9
1.1.2 Research Scope 10
1.2 Research Methodology 13
1.2.1 Overview of Market Research Methodology 13
1.2.2 Market Assumption 14
1.2.3 Secondary Data 14
1.2.4 Primary Data 14
1.2.5 Data Filtration and Model Design 15
1.2.6 Market Size/Share Estimation 16
1.2.7 Research Limitations 17
1.3 Executive Summary 18
2 Market Overview and Dynamics 21
2.1 Market Size and Forecast 21
2.1.1 Impact of COVID-19 on World Economy 22
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter’s Fiver Forces Analysis 39
3 Segmentation of Global Market by Source 43
3.1 Market Overview by Source 43
3.2 Human 45
3.3 Humanized 46
3.4 Chimeric 47
3.5 Murine 48
4 Segmentation of Global Market by Category 49
4.1 Market Overview by Category 49
4.2 Branded mAbs 51
4.3 Biosimilar mAbs 52
5 Segmentation of Global Market by Production Type 53
5.1 Market Overview by Production Type 53
5.2 In Vitro Production 55
5.3 In Vivo Production 56
6 Segmentation of Global Market by Application 57
6.1 Market Overview by Application 57
6.2 Cancer 59
6.2.1 Breast Cancer 61
6.2.2 Colorectal Cancer 62
6.2.3 Lung Cancer 63
6.2.4 Ovarian Cancer 64
6.2.5 Other Cancer Types 65
6.3 Autoimmune Diseases 66
6.4 Inflammatory Diseases 67
6.5 Infectious Diseases 68
6.6 Other Applications 69
7 Segmentation of Global Market by End User 70
7.1 Market Overview by End User 70
7.2 Hospitals 72
7.3 Research Institutes 73
7.4 Other End Users 74
8 Segmentation of Global Market by Region 75
8.1 Geographic Market Overview 2019-2030 75
8.2 North America Market 2019-2030 by Country 79
8.2.1 Overview of North America Market 79
8.2.2 U.S. 83
8.2.3 Canada 86
8.2.4 Mexico 88
8.3 European Market 2019-2030 by Country 90
8.3.1 Overview of European Market 90
8.3.2 Germany 94
8.3.3 U.K. 96
8.3.4 France 98
8.3.5 Spain 100
8.3.6 Italy 102
8.3.7 Russia 104
8.3.8 Rest of European Market 106
8.4 Asia-Pacific Market 2019-2030 by Country 108
8.4.1 Overview of Asia-Pacific Market 108
8.4.2 Japan 112
8.4.3 China 115
8.4.4 Australia 117
8.4.5 India 119
8.4.6 South Korea 121
8.4.7 Rest of APAC Region 123
8.5 South America Market 2019-2030 by Country 125
8.5.1 Argentina 128
8.5.2 Brazil 130
8.5.3 Chile 132
8.5.4 Rest of South America Market 134
8.6 MEA Market 2019-2030 by Country 135
8.6.1 UAE 138
8.6.2 Saudi Arabia 140
8.6.3 South Africa 142
8.6.4 Other National Markets 144
9 Competitive Landscape 145
9.1 Overview of Key Vendors 145
9.2 New Product Launch, Partnership, Investment, and M&A 148
9.3 Company Profiles 149
Abbott Laboratories 149
AbbVie, Inc. 151
Amgen Inc. 152
AstraZeneca plc 153
Bayer AG 154
Bristol-Myers Squibb Company 155
Eli Lilly 156
F. Hoffmann-La Roche Ltd. 157
GlaxoSmithKline Plc 158
Johnson & Johnson 159
Merck & Co., Inc. 160
Mylan N.V 161
Norvatis AG 162
Pfizer 163
Sanofi S.A. 164
RELATED REPORTS 165
Why Choose Kenneth Research ?
-
Insight with Impact : We don’t just gather data — we uncover stories, trends, and opportunities that fuel business growth.
-
Experts Who Get It : Our team speaks your industry’s language and knows what really matters to your customers and market.
-
Custom-Built for You : Forget one-size-fits-all. We craft research and consulting solutions as unique as your business vision.
-
Partners, Not Just Providers : We work with you, not for you — collaborating closely to turn insights into smart, strategic moves.
-
Results That Speak : Our work powers brands, startups, and industry leaders alike — with a track record of ideas that work in the real world.
Report ID: 10352320 |
Published Date: 21 Oct 2022 |
Report Format: |
Delivery Timeline: 48-72 Business Hours
